Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

  • Technology appraisal guidance
  • TA214
  • Published: 
Download guidance (PDF)

8 Review of guidance

The guidance on this technology will be considered for review in July 2013.

Andrew Dillon
Chief Executive
February 2011